Skip to content
Haloperidol
Haldol (haloperidol) is a small molecule pharmaceutical. Haloperidol was first approved as Haldol on 1982-01-01. It is used to treat child behavior disorders, psychotic disorders, schizophrenia, schizophrenia spectrum and other psychotic disorders, and substance withdrawal syndrome amongst others in the USA. The pharmaceutical is active against D(3) dopamine receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, and D(4) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1A, D(1A) dopamine receptor, D(1B) dopamine receptor, histamine H1 receptor, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 2B, potassium voltage-gated channel subfamily H member 1, and G protein-activated inward rectifier potassium channel 2.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
signs and symptoms pathological conditionsD013568
chemically-induced disordersD064419
mental disordersD001523
Trade Name
FDA
EMA
Haldol (generic drugs available since 1986-06-10, discontinued: Haldol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Haloperidol
Tradename
Company
Number
Date
Products
HALDOLJohnson & JohnsonN-015921 DISCN1982-01-01
6 products, RLD
HALDOL SOLUTABJohnson & JohnsonN-017079 DISCN1982-01-01
1 products
Hide discontinued
Haloperidol decanoate
Tradename
Company
Number
Date
Products
HALDOLJohnson & JohnsonN-018701 RX1986-01-14
2 products, RLD, RS
Haloperidol lactate
Tradename
Company
Number
Date
Products
HALDOLJohnson & JohnsonN-015923 DISCN1982-01-01
1 products, RLD
HALDOLJohnson & JohnsonN-015922 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
haldol decanoateNew Drug Application2020-11-24
haloperidol decanoateANDA2023-06-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
child behavior disorders—D002653—
psychotic disorders—D011618F20.81
schizophreniaEFO_0000692D012559F20
schizophrenia spectrum and other psychotic disorders—D019967—
substance withdrawal syndromeEFO_0005800D013375—
tourette syndromeEFO_0004895D005879F95.2
vomitingHP_0002013D014839R11.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AD: Butyrophenone derivatives, antipsychotics
— N05AD01: Haloperidol
HCPCS
Code
Description
J1630
Injection, haloperidol, up to 5 mg
J1631
Injection, haloperidol decanoate, per 50 mg
Clinical
Clinical Trials
129 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20—1915833
DeliriumD003693R41.0—7127427
Psychotic disordersD011618F20.811147114
Psychomotor agitationD011595——1225
Bipolar disorderD001714EFO_0000289F30.9——2114
NauseaD009325HP_0002018R11.01—12—4
Postoperative nausea and vomitingD020250EFO_0004888———213
Migraine disordersD008881EFO_0003821G43———3—3
Cognitive dysfunctionD060825G31.84——1113
DepressionD003863F33.9——11—2
Show 15 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80—34—16
ConfusionD003221F44.89——2——2
Critical illnessD016638—11——2
DementiaD003704F03——1——1
Psychophysiologic disordersD011602F45.9——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Mood disordersD019964EFO_0004247F30-F39—11——1
Medication adherenceD055118EFO_0006344——1——1
Hip fracturesD006620EFO_0003964S72.00——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Movement disordersD009069EFO_0004280G25—1——12
Intellectual disabilityD008607F73—1———1
Artificial respirationD012121—1———1
Critical careD003422—1———1
Ventilator weaningD015300—1———1
GamblingD005715F63.0—1———1
Drug-induced akathisiaD017109EFO_1000903G25.71—1———1
Cognition disordersD003072—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2———13
Therapeutic equivalencyD0138102————2
PlacebosD0109191————1
Huntington diseaseD006816G101————1
Tobacco use disorderD014029F171————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DyslipidemiasD050171HP_0003119————22
Insulin resistanceD007333EFO_0002614————22
StrokeD020521EFO_0000712I63.9————11
Female genital diseasesD005831EFO_0009549N85————11
RecurrenceD012008————11
ObesityD009765EFO_0001073E66.9————11
Metabolic syndromeD024821EFO_0000195E88.81————11
Lactic acidosisD000140EFO_1000036E87.20————11
Patient complianceD010349————11
ChoreaD002819EFO_0004152G25.5————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHALOPERIDOL
INNhaloperidol
Description
Haloperidol is a compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. It has a role as a serotonergic antagonist, a first generation antipsychotic, a dopaminergic antagonist, an antidyskinesia agent and an antiemetic. It is a hydroxypiperidine, an organofluorine compound, an aromatic ketone, a tertiary alcohol and a member of monochlorobenzenes.
Classification
Small molecule
Drug classantipsychotics (haloperidol type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
Identifiers
PDB6LUQ
CAS-ID52-86-8
RxCUI5093
ChEMBL IDCHEMBL54
ChEBI ID5613
PubChem CID3559
DrugBankDB00502
UNII IDJ6292F8L3D (ChemIDplus, GSRS)
Target
Agency Approved
DRD3
DRD3
DRD2
DRD2
HTR2A
HTR2A
DRD4
DRD4
Organism
Homo sapiens
Gene name
DRD3
Gene synonyms
NCBI Gene ID
1814
Protein name
D(3) dopamine receptor
Protein synonyms
Dopamine D3 receptor, essential tremor 1
Uniprot ID
Q4VBM8
Mouse ortholog
Drd3 (13490)
D(3) dopamine receptor (P30728)
Alternate
HTR1A
HTR1A
DRD1
DRD1
DRD5
DRD5
HRH1
HRH1
HTR7
HTR7
HTR1D
HTR1D
HTR2B
HTR2B
KCNH1
KCNH1
KCNJ6
KCNJ6
Organism
Homo sapiens
Gene name
HTR1A
Gene synonyms
ADRB2RL1, ADRBRL1
NCBI Gene ID
3350
Protein name
5-hydroxytryptamine receptor 1A
Protein synonyms
5-HT1a receptor, 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled, G-21, guanine nucleotide-binding regulatory protein-coupled receptor, Serotonin receptor 1A
Uniprot ID
Q6LAE7
Mouse ortholog
Htr1a (15550)
5-hydroxytryptamine receptor 1A (Q8BGS4)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 28,626 documents
View more details
Safety
Black-box Warning
Black-box warning for: Haldol decanoate, Haloperidol decanoate
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details